4-氯羰酰四氢-吡啶羧酸苄酯 | 10314-99-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氯羰酰四氢-吡啶羧酸苄酯
• 英文名称: benzyl 4-(chlorocarbonyl)piperidine-1-carboxylate
• 英文别名: 1-[(benzyloxy)carbonyl]piperidine-4-carbonyl chloride；1-benzyloxycarbonylpiperidine-4-carboxylic acid chloride；benzyl 4-carbonochloridoylpiperidine-1-carboxylate
• CAS: 10314-99-5
• 化学式: C₁₄H₁₆ClNO₃
• mdl: MFCD02677707
• 分子量: 281.739
• InChiKey: KUBUQFFBRSHOMJ-UHFFFAOYSA-N

物化性质

• 沸点：
  396.6±42.0 °C(Predicted)
• 密度：
  1.269±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  C
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R34
• 海关编码：
  2933399090
• 危险品运输编号：
  UN 3265
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H314
• 储存条件：
  储存温度应控制在2-8°C，并请避免光线直射。

SDS

Name:	Benzyl 4-(chlorocarbonyl)tetrahydro-1(2H)-pyridinecarboxylate 95+% Material Safety Data Sheet
Synonym:	4-Chlorocarbonylpiperidine-1-carboxylic acid benzyl este
CAS:	10314-99-5

Section 1 - Chemical Product MSDS Name:Benzyl 4-(chlorocarbonyl)tetrahydro-1(2H)-pyridinecarboxylate 95+% Material Safety Data Sheet
Synonym:4-Chlorocarbonylpiperidine-1-carboxylic acid benzyl este

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
10314-99-5	Benzyl 4-(chlorocarbonyl)tetrahydro-1(	95+%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area. Store under nitrogen.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 10314-99-5: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Viscous liquid
Color: Clear
Odor: characteristic odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C14H16ClNO3
Molecular Weight: 282

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents, reducing agents, acids, bases, alcohols, amines.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide, acrid smoke and fumes.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 10314-99-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Benzyl 4-(chlorocarbonyl)tetrahydro-1(2H)-pyridinecarboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3265
Packing Group: III
IMO
Shipping Name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3265
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3265
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 10314-99-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 10314-99-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 10314-99-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氯羰酰四氢-吡啶羧酸苄酯 在 palladium on activated charcoal sodium tetrahydroborate 、 茴香硫醚 、 氢气 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 甲苯 为溶剂， -2.0~35.0 ℃ 、275.79 kPa 条件下， 反应 39.5h， 生成 螺[吲哚啉-3,4’-哌啶]-1’-羧酸苄酯
  参考文献：
  名称：

  合成基于口服螺螺吲哚的生长激素促分泌素MK-677

  摘要：

  默克生长激素促分泌素的制备；描述了MK-677。费歇尔吲哚/还原为基础的策略提供了这种有效化合物的新型螺二氢吲哚核。该优化的序列仅需要分离一种中间体10并从异二十二烯酸3提供48％的总收率的MK-677 。

  DOI：

  10.1016/s0040-4020(97)00359-1
• 作为产物：
  描述：

  1-Cbz-4-哌啶甲酸甲酯 在 lithium hydroxide 、 草酰氯 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 生成 4-氯羰酰四氢-吡啶羧酸苄酯
  参考文献：
  名称：

  POTENT NON-UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE

  摘要：

  本发明涉及通过抑制可溶性环氧合酶（sEH）的活性而具有血管舒张和抗炎效果的化合物。本发明还涉及识别此类化合物的方法，以及使用此类化合物治疗与血管舒张、炎症和/或内皮细胞功能障碍相关的疾病。特别是非限制性实施例中，发明的组成成分可用于治疗高血压。

  公开号：

  US20160052883A1

文献信息

• Novel Tricyclic Compounds
  申请人：Wishart Neil

  公开号：US20090312338A1

  公开（公告）日：2009-12-17

  The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  这项发明提供了一个符合Formula (I)的化合物，其中包括药用盐、前药、生物活性代谢物、立体异构体和同分异构体，其中变量在此处定义。该发明的化合物对治疗免疫和肿瘤疾病有用。
• [EN] INHIBITORS OF PROTEIN KINASES<br/>[FR] INHIBITEURS DE PROTÉINE KINASES
  申请人：INGENIUM PHARMACEUTICALS GMBH

  公开号：WO2009047359A1

  公开（公告）日：2009-04-16

  Compounds of general Formula I, wherein R1, R2, R3, x, A and Ra are as defined herein are inhibitors of cyclin-dependent kinases and are useful for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.

  通式I的化合物，其中R1、R2、R3、x、A和Ra的定义如本文所述，是细胞周期依赖性激酶的抑制剂，可用于预防和/或治疗任何类型的疼痛、炎症性疾病、免疫性疾病、增殖性疾病、传染性疾病、心血管疾病和神经退行性疾病。
• [EN] INHIBITORS OF Akt ACTIVITY<br/>[FR] INHIBITEURS DE L'ACTIVITE DE AKT
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2005011700A1

  公开（公告）日：2005-02-10

  Invented are novel 1 H-imidazo[4,5-c]pyridin-2-yI compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

  发明了新型的1H-咪唑[4,5-c]吡啶-2-基化合物，这些化合物用作蛋白激酶B活性的抑制剂，并用于治疗癌症和关节炎。
• Nickel-Catalyzed Decarboxylative Alkenylation of Anhydrides with Vinyl Triflates or Halides
  作者：Hui Chen、Shuhao Sun、Xuebin Liao

  DOI：10.1021/acs.orglett.9b01048

  日期：2019.5.17

  Decarboxylative cross-coupling of aliphatic acid anhydrides with vinyl triflates or halides was accomplished via nickel catalysis. This methodology works well with a broad array of substrates and features abundant functional group tolerance. Notably, our approach addresses the issue of safe and environmental installation of methyl or ethyl group into molecular scaffolds. The method possesses high chemoselectivity

  脂肪族酸酐与乙烯基三氟甲磺酸酯或卤化物的脱羧交叉偶联是通过镍催化实现的。这种方法学适用于各种各样的底物，并且具有丰富的官能团耐受性。值得注意的是，我们的方法解决了将甲基或乙基安全环保地安装到分子支架中的问题。当涉及脂族/芳族混合酸酐时，该方法具有对烷基的高化学选择性。此外，我们的策略可以改变各种酮。
• Discovery of Novel Thieno[2,3-d]pyrimidin-4-yl Hydrazone-Based Cyclin-Dependent Kinase 4 Inhibitors: Synthesis, Biological Evaluation and Structure-Activity Relationships
  作者：Takao Horiuchi、Yasuyuki Takeda、Noriyasu Haginoya、Masaki Miyazaki、Motoko Nagata、Mayumi Kitagawa、Kouichi Akahane、Kouichi Uoto

  DOI：10.1248/cpb.59.991

  日期：——

  The design, synthesis, and evaluation of novel thieno[2,3-d]pyrimidin-4-yl hydrazone analogues as cyclin-dependent kinase 4 (CDK4) inhibitors are described. In continuing our program aim to search for potent CDK4 inhibitors, the introduction of a thiazole group at the hydrazone part has led to marked enhancement of chemical stability. Furthermore, by focusing on the optimization at the C-4' position

  描述，设计和合成新型噻吩并[2,3-d]嘧啶-4-基类似物作为细胞周期蛋白依赖性激酶4（CDK4）抑制剂。在继续我们的计划以寻找有效的CDK4抑制剂的过程中，在part部分引入噻唑基团导致化学稳定性显着提高。此外，通过集中于噻唑环的C-4'位置和噻吩并[2,3-d]嘧啶部分的C-6位置的优化，已确定化合物35在HCT116异种移植模型中有效细胞。在本文中，我们对合成化合物的效价，选择性和结构活性关系进行了讨论。